China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

While the word “mutation” may conjure up alarming notions, a mutation in brain immune cells serves a positive role in protecting people against Alzheimer’s disease.

Diagnostics manufacturer Quidel reported after the close of the market on Thursday that its fourth quarter revenues fell more than 21 percent year over year due primarily to shift in product mix and decreased COVID-19 product sales.

On February 17, 2022, Roche Diagnostics China announced in Shanghai that it had reached a strategic partnership with Sanomede Medical Technology Co., Ltd. (hereinafter referred to as "Sanomede") to jointly launch a new RS600 Lab Automation System (LAS) for Chinese market.

Recently, Hong Kong has been hit by the epidemic continuously. On February 16, Kang Keren, senior vice president of Wondfo Biotech, said that in response to the epidemic in Hong Kong, Wondfo's "Anti-epidemic pioneer" is preparing to go to the front line and guarantee supply.

The European Union’s In Vitro Diagnostics Regulation (IVDR) is set to take effect May 26, 2022, but a recent effort to amend the transitional provisions of the new regulation may bring some relief.

Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution

Researchers at the University of Toronto have identified hundreds of new proteins that could play a role in cystic fibrosis, and which may shed light on why some patients respond better than others to current therapies.

Pacific Biosciences reported after the close of the market on Tuesday that its fourth quarter 2021 revenues grew 33 percent year over year, while its full-year revenues jumped 65 percent.

On 12 February, the second meeting between the Mainland and Hong Kong on the COVID-19 outbreak as held in Shenzhen as the COVID-19 continued to spread in Hong Kong and confirmed cases continued to soar.

At the end of the reporting period, the total assets of Wantai Biopharmwere CNY 7.047 billion, an increase of 101.13% over the beginning of the period.